TC Biopharm HoldingsTCBWFPreferred / convertible
13F holders, Q3 2024 (September 30)6holders −2
1new positions
3sold out
$0.02avg. 13F price*
At the end of Q3 2024, 6 institutions reported holding TC Biopharm Holdings Ltd. (TCBWF) in their 13F filings, down 2 from Q2 2024. 1 opened new positions and 3 sold out. The largest holders were Kepos Capital LP ($9K), Nantahala Capital Management, LLC ($4K) and Csenge Advisory Group ($472).
- Company
- TC Biopharm Holdings Ltd.
- CUSIP
- 87807D111
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $472 |
| Exits | 3 | $761 |
All 13F filers, Q2 2024 → Q3 2024: 20,009 shares bought and 81,761 shares sold, net −61,752 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Kepos Capital LP | — | No change | 470,588 | $9K |
| Nantahala Capital Management, LLC | — | No change | 235,294 | $4K |
| Csenge Advisory Group | — | New | 18,862 | $472 |
| Altium Capital Management LLC | — | No change | 18,823 | $343 |
| UBS Group AG | — | Add +3373.5% | 1,181 | $21 |
| Bank of America Corp. | — | Reduce -81.4% | 71 | $1 |
"% of holder's portfolio" is TCBWF's weight in each manager's 13F, not the share of TC Biopharm Holdings Ltd. the manager owns.